ADMA Biologics (ADMA)
(Real Time Quote from BATS)
$19.54 USD
+0.25 (1.30%)
Updated Sep 25, 2024 02:14 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADMA 19.54 +0.25(1.30%)
Will ADMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Here's Why Momentum in Adma Biologics (ADMA) Should Keep going
Other News for ADMA
Millennium Management LLC Acquires Shares in ADMA Biologics Inc
American Century Small Cap Growth Fund Q2 2024 Commentary
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
ADMA Biologics Set to Join S&P SmallCap 600 Index
ADMA Biologics to join S&P SmallCap 600 index